Importance of quantitative genetic variations in the etiology of hypertension

Kidney International

Volumn 58, Issue 6, 2000, Pages 2265-2280

  Smithies, O ^a   Kim, H S ^a   Takahashi, N ^a   Edgell, M H ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

ACE inhibitors; Angiotensinogen; Blood pressure; Candidate gene; Computerized gene simulation; Essential hypertension; Genetic etiology

Indexed keywords

ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE;

ANIMAL MODEL; BLOOD PRESSURE; CARDIOVASCULAR FUNCTION; ESSENTIAL HYPERTENSION; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HUMAN; HYPERTENSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; REVIEW;

EID: 0033667449     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00411.x     Document Type: Article

References (115)

1. The hypertension detection and follow-up program: A progress report
2. Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase
3. Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III
4. Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis
5. Molecular genetics of human blood pressure variation
6. Molecular basis of human hypertension: Role of angiotensinogen
7. Dinucleotide repeat polymorphism in the human angiotensinogen gene
8. Insertion of DNA sequences into the human chromosomal beta-globin locus by homologous recombination
9. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells
10. Targeted correction of a mutant HPRT gene in mouse embryonic stem cells
11. Molecular cloning of the mouse angiotensinogen gene
12. Targeted modification of human chromosomal genes
13. Targeted gene duplication and disruption for analyzing quantitative genetic traits in mice
14. Yeast transformation: A model system for the study of recombination
15. Double-strand gap repair in a mammalian gene targeting reaction
16. Genetic control of blood pressure and the angiotensinogen locus
17. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro
18. Seven lessons from two candidate genes in human essential hypertension: Angiotensinogen and epithelial sodium channel
19. Homeostasis in mice with genetically decreased angiotensinogen is primarily by an increased number of renin-producing cells
20. The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor
21. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels
22. Angiotensin-converting enzyme gene mutations, blood pressures, and cardiovascular homeostasis
23. Male-female differences in fertility and blood pressure in ACE-deficient mice
24. A strategy for increasing an in vivo flux by genetic manipulations: The tryptophan system of yeast
25. Theodore Cooper Memorial Lecture: A mouse view of hypertension
26. Measurement and characterization of angiotensin peptides in plasma
27. A mutation of angiotensinogen in a patient with preeclampsia leads to altered kinetics of the renin-angiotensin system
28. Kinetic analysis of the reaction of human renin with low and high molecular weight human angiotensinogen
29. Is angiotensinogen a renin inhibitor and not the substrate for renin?
30. Angiotensin I-converting enzyme insertion/deletion polymorphism: Clinical implications
31. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides
32. Natriuretic peptide receptor 1 expression influences blood pressures of mice in a dose-dependent manner
33. Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2
34. Uncompensated polyuria in a mouse model of Bartter's syndrome
35. Bumetanide: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use
36. Apo E structure determines VLDL clearance and atherosclerosis risk in mice
37. Gene targeting approaches to complex genetic diseases: Atherosclerosis and essential hypertension
38. Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells
39. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor
40. Decreased blood pressure response in mice deficient of the alpha1b-adrenergic receptor
41. Abnormal regulation of the sympathetic nervous system in alpha2A-adrenergic receptor knockout mice
42. Cardiovascular regulation in mice lacking alpha2-adrenergic receptor subtypes b and c
43. Targeted disruption of the beta 2 adrenergic receptor gene
44. Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia
45. Regulation of blood pressure by the type 1A angiotensin II receptor gene
46. Angiotensin II responses in AT1A receptor-deficient mice: A role for AT1B receptors in blood pressure regulation
47. Targeting deletion of angiotensin type 1B receptor gene in the mouse
48. Reduced growth, abnormal kidney structure, and type 2 (AT:2) angiotensin receptor-mediated blood pressure regulation in mice lacking both AT1A and AT1B receptors for angiotensin II
49. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor
50. Behavioural and cardiovascular effects of disrupting the angiotensin II type- 2 receptor in mice
51. Immunological development and cardiovascular function are normal in annexin VI null mutant mice
52. Hypertension and endothelial dysfunction in apolipoprotein E knockout mice
53. Beta-Arrestin1 knockout mice appear normal but demonstrate altered cardiac responses to beta-adrenergic stimulation
54. Chronically increased secretion of vasopressin in transgenic mice
55. Cardiovascular phenotype of a mouse strain with disruption of bradykinin B2-receptor gene
56. Enhanced blood pressure sensitivity to deoxycorticosterone in mice with disruption of bradykinin B2 receptor gene
57. Dilated and failing cardiomyopathy in bradykinin B(2) receptor knockout mice
58. Early onset salt-sensitive hypertension in bradykinin B(2) receptor null mice
59. Hypotension in transgenic mice overexpressing human bradykinin B2 receptor
60. Mice lacking bombesin receptor subtype-3 develop metabolic defects and obesity
61. Mice lacking alpha-calcitonin gene-related peptide exhibit normal cardiovascular regulation and neuromuscular development
62. Increased blood pressure in alpha-calcitonin gene-related peptide/calcitonin gene knockout mice
63. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice
64. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor- 2
65. Role of the D1A dopamine receptor in the pathogenesis of genetic hypertension
66. Disruption of the dopamine D3 receptor gene produces renin-dependent hypertension
67. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1
68. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension
69. Elevation of blood pressure by genetic and pharmacological disruption of the ETB receptor in mice
70. Fibroblast growth factor 2 control of vascular tone
71. Vascular remodeling in the growth hormone transgenic mouse
72. GLUT 4 heterozygous knockout mice develop muscle insulin resistance and diabetes
73. Hypertension in mice lacking 11beta-hydroxysteroid dehydrogenase type 2
74. Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1
75. Human tissue kallikrein induces hypotension in transgenic mice
76. Tissue kallikrein-binding protein reduces blood pressure in transgenic mice
77. Male-associated hypertension in LDL-R deficient mice
78. The control of microvascular permeability and blood pressure by neutral endopeptidase
79. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase
80. Elevated blood pressures in mice lacking endothelial nitric oxide synthase
81. Hypertension in mice lacking the gene for endothelial nitric oxide synthase
82. Hypotension and reduced nitric oxide-elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase
83. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension
84. Salt-sensitive hypertension in ANP knockout mice: Potential role of abnormal plasma renin activity
85. Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes
86. Molecular cloning of the complementary DNA and gene that encode mouse brain natriuretic peptide and generation of transgenic mice that overexpress the brain natriuretic peptide gene
87. Cardiac fibrosis in mice lacking brain natriuretic peptide
88. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide
89. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A
90. The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system
91. Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor
92. Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow obese mice
93. Identification of specific EP receptors responsible for the hemodynamic effects of PGE2
94. Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor
95. Reproductive failure and reduced blood pressure in mice lacking the EP2 prostaglandin E2 receptor
96. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor
97. Targeted overexpression of parathyroid hormone-related protein (PTHrP) to vascular smooth muscle in transgenic mice lowers blood pressure and alters vascular contractility
98. Reduced blood pressure and increased sensitivity of the vasculature to parathyroid hormone-related protein (PTHrP) in transgenic mice overexpressing the PTH/PTHrP receptor in vascular smooth muscle
99. Renin-dependent cardiovascular functions and renin-independent blood-brain barrier functions revealed by renin-deficient mice
100. Renin-1 is essential for normal renal juxtaglomerular cell granulation and macula densa morphology
101. Targeted inactivation of the Ren-2 gene in mice
102. Salt restriction induces pseudohypoaldosteronism type 1 in mice expressing low levels of the beta-subunit of the amiloride-sensitive epithelial sodium channel
103. 2+-ATPase isoform 3
104. Mice lacking the basolateral Na-K-2Cl cotransporter have impaired epithelial chloride secretion and are profoundly deaf
105. - cotransporter
106. - cotransporter of the distal convoluted tubule
107. Salt-sensitive hypertension in transgenic mice overexpressing Na(+)-proton exchanger
108. + exchanger
109. Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2